Reston, VA (October 10, 2025)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Many Patients Benefit from Continuing PSMA Therapy Despite Early PSA Rise
A new study from the ProsTIC registry examined men with advanced prostate cancer receiving 177Lu-PSMA-617 therapy who showed no early PSA decline after the first treatment cycle. Researchers found that nearly half of the men later achieved significant PSA reductions or pain relief, highlighting the importance of continuing therapy beyond early PSA results.
New PET/CT Scan May Improve Surgery Decisions in Pancreatic Cancer
In patients with pancreatic ductal adenocarcinoma, 68Ga-FAPI PET/CT uncovered hidden metastases missed by standard CT in nearly one-third of cases, sparing them unnecessary surgery. The scan's uptake also correlated with tumor aggressiveness, suggesting this advanced imaging could better guide treatment planning and identify patients most likely to benefit from surgery.
New Procedure Guideline Highlights Molecular Imaging Breakthroughs for Kidney Tumors
A new procedure guideline outlines how molecular imaging can better distinguish aggressive kidney cancers from benign lesions. By combining CAIX-targeted tracers such as 89Zr-girentuximab with mitochondrial agents like 99mTc-sestamibi, clinicians can improve diagnosis and treatment decisions. The guideline also points to AI-driven imaging advances for future kidney cancer care.
Advanced PSMA PET/CT Scan Changes Treatment Plans for High-Risk Prostate Cancer
In a study of 160 men with newly diagnosed high-risk prostate cancer, 18F-PSMA PET/CT imaging revealed previously unseen metastases in one-quarter of patients compared with standard bone scans. The improved detection, especially of lymph node spread, led to major changes in treatment plans for more than 10 percent of participants.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
